Mr. Enloe has more than 20 years of executive management experience, primarily in biotechnology, drug development, and GMP manufacturing. Most recently, he served as head of the Viral Therapeutics Business Unit at Lonza AG, which provides process development, scale-up and GMP manufacture of viral-based biologics. He was also the founder and chief executive officer of Vivante GMP Solutions, which he sold to Lonza in 2010. Prior to this, he was president and chief executive officer of Introgen Therapeutics.
"We are delighted to welcome David as the new leader of Ajinomoto Althea's management team," said Dr. Hiroshi Shiragami, co-chair of Ajinomoto Althea. "His unique depth of experience in the biotechnology industry, leadership abilities, financial management, manufacturing and contractual negotiation skills will be instrumental in supporting further expansion of our business."